0001209191-23-032726.txt : 20230526 0001209191-23-032726.hdr.sgml : 20230526 20230526210056 ACCESSION NUMBER: 0001209191-23-032726 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230525 FILED AS OF DATE: 20230526 DATE AS OF CHANGE: 20230526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Castagna Michael CENTRAL INDEX KEY: 0001674282 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50865 FILM NUMBER: 23971173 MAIL ADDRESS: STREET 1: 25134 RYE CANYON LOOP STREET 2: SUITE 300 CITY: VALENCIA STATE: CA ZIP: 91355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MANNKIND CORP CENTRAL INDEX KEY: 0000899460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133607736 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 BUSINESS PHONE: 818-661-5000 MAIL ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-25 0 0000899460 MANNKIND CORP MNKD 0001674282 Castagna Michael 1 CASPER STREET DANBURY CT 06810 1 1 0 0 Chief Executive Officer 1 Common Stock, $.01 Par Value 2023-05-25 4 A 0 345000 0.00 A 2676735 D Common Stock, $.01 Par Value 2023-05-25 4 S 0 75000 4.5929 D 2601735 D Common Stock, $.01 Par Value 2023-05-26 4 S 0 75000 4.4978 D 2526735 D Performance Restricted Stock Unit 2023-05-25 4 A 0 422000 0.00 A Common Stock, $.01 Par Value 422000 422000 D Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Transaction occurred pursuant to a Rule 10B5-1 Plan adopted on December 5, 2022. The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. /s/ Michael Castagna 2023-05-26